S. Pledge

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer

Rosalind Glasspool, Robert Brown, Martin Gore et al. · British Journal of Cancer · 2014 · 117 citations · Full text

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG

Susana Banerjee, G. Rustin, James Paul et al. · Annals of Oncology · 2012 · 46 citations · Full text

Oncology, Anzgog Study, Medicine +9

The impact of virtual simulation in palliative radiotherapy for non-small-cell lung cancer

M. McJury, P.M. Fisher, S. Pledge et al. · Radiotherapy and Oncology · 2001 · 22 citations

Adaptive Radiotherapy, Non-small-cell Lung Cancer, Medical Imaging +13

Randomized phase II study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer

Rosalind Glasspool, Martin Gore, Gordon Rustin et al. · Journal of Clinical Oncology · 2009 · 17 citations

Carboplatin Auc 6, Clin Cancer Res, Medicine +15

Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Paul Tappenden, S Harnan, Shijie Ren et al. · PharmacoEconomics · 2016 · 14 citations

Brca 1, Medicine, Cancer Management +9